Associate Professor, Division of Rheumatology and Immunology

543 Taylor Ave.Kevin Hackshaw whitecoat
Columbus, OH 43203

614-293-4837
Fax: 614-293-3125
Kevin.Hackshaw@osumc.edu

Special interests: 

Dr. Hackshaw joined the faculty in 1990. His current research involves fibroblast growth factors (FGFs), which are well-described modifiers of angiogenesis, and endothelial cell proliferation. He and his colleagues are investigating these and other factors roles as neurotrophins in pain propagation. Dr. Hackshaw's specialty interests are fibromyalgia, chronic pain, systemic lupus erythematosus and vasculitis. His research interests center around the mechanisms of neurotrophins in propagating chronic pain states.

Education: 

MD: Baylor College of Medicine, Medicine, 1983

University of Colorado Health Sciences Center, Rheumatology, 1990

PubMed list of publications

View clinical bio

Lupus

  • A phase two, randomized study to evaluate the efficacy and safety of MEDI?546 in subjects with systemic lupus erythematosus medImmune
  • A phase three, multi-center, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of Belimumab  (HGS1006) administered subcutaneously (SC) to subjects with systemic lupus erythematosus human genome science

Rheumatoid Arthritis

A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA) Roche

Gout

  • A phase three randomized, double-blind, multicenter, placebo-controlled, combination study to evaluate the efficacy and safety of Lesinurad and Febuxostat compared to Febuxostat alone at lowering serum uric acid and resolving tophi in subjects with tophaceous gout
  • A phase three randomized, double-blind, multicenter, placebo-controlled study to assess the efficacy and safety of Lesinurad monotherapy compared to placebo in subjects with gout and an intolerance or contraindication to a xanthine oxidase inhibitor
  • A phase three randomized, double-blind, multicenter, placebo-controlled, combination study to evaluate the efficacy and safety of Lesinurad and Allopurinol compared to Allopurinol alone in subjects with gout who have had an inadequate hypouricemic response to standard of care Allopurinol

Contact

Holly Steigelman, CCRP, MACPR
Lead Clinical Research Coordinator
Holly.Steigelman@osumc.edu
614-685-6987

Kelly Morris
Clinical Research Assistant
Kelly.Morris@osumc.edu
614-685-6068